THE SCREEN · BRIEFSPECIMEN
Thornlark Diagnostics
Thornlark Diagnostics, Inc., a Delaware corporation incorporated March 14, 2024, Austin, Texas. Eleven full-time employees.
USD 2,500,000 seed at a USD 14,000,000 post-money valuation. No lead identified. A USD 750,000 SAFE from 2025 converts at a USD 9,000,000 cap, which takes roughly 5.4% off the founders before new money arrives.
Screened August 8, 2026 · Overall B-
| Category | Grade | Rationale |
|---|---|---|
| Team | B | The CTO has eleven peer-reviewed papers in assay chemistry, and the commercial lead carried a diagnostics line to USD 30 million. But no one on the team is named on an FDA-cleared 510(k), and the plan needs that in nineteen months. |
| Market | B | Roughly 8,900 US urgent-care sites and a reimbursable billing code that already pays, but the deck's USD 4.1 billion market counts the whole panel, and Thornlark addresses one analyte on it. |
The Screen, with an exit read
Is the company worth real time, and can you make money at this price?